Malondialdehyde, Antioxidant Defense System Components and Their Relationship with Anthropometric Measures and Lipid Metabolism Biomarkers in Apparently Healthy Women
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design
2.2. Study Participants
2.3. Anthropometric Parameters and Preparation of Blood Samples
2.4. Lipid Metabolism Biomarker Analysis
2.5. Serum Antioxidant and Oxidative Stress Biomarker Analysis
2.6. Statistical Analysis
3. Results
3.1. Study Group Characteristics
3.2. Age, Anthropometric Parameters, Antioxidative Defense System Biomarkers and MDA
3.3. Lipid Metabolism Biomarkers, Antioxidative Defense System Biomarkers and MDA
3.4. Lipid Peroxidation and Antioxidant Defense System Biomarkers and BMI, Waist Circumference and Dyslipidemia
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- World Heart Federation. World Heart Report 2023: Confronting the World’s Number One Killer; World Heart Federation: Geneva, Switzerland, 2023. [Google Scholar]
- Jebari-Benslaiman, S.; Galicia-García, U.; Larrea-Sebal, A.; Olaetxea, J.R.; Alloza, I.; Vandenbroeck, K.; Benito-Vicente, A.; Martín, C. Pathophysiology of atherosclerosis. Int. J. Mol. Sci. 2022, 23, 3346. [Google Scholar] [CrossRef] [PubMed]
- Steinberg, D. Atherogenesis in perspective: Hypercholesterolemia and inflammation as partners in crime. Nat. Med. 2002, 8, 1211–1217. [Google Scholar] [CrossRef] [PubMed]
- Libby, P.; Buring, J.; Badimon, L.; Hansson, G.K.; Deanfield, J.; Bittencourt, M.S.; Tokgözoğlu, L.; Lewis, E.F. Atherosclerosis. Nat. Rev. Dis. Primers 2019, 5, 56. [Google Scholar] [CrossRef]
- Björkegren, J.L.; Lusis, A.J. Atherosclerosis: Recent developments. Cell 2022, 185, 1630–1645. [Google Scholar] [CrossRef] [PubMed]
- Badimon, L.; Vilahur, G. Thrombosis formation on atherosclerotic lesions and plaque rupture. J. Intern. Med. 2014, 276, 618–632. [Google Scholar] [CrossRef] [PubMed]
- Poznyak, A.V.; Grechko, A.V.; Orekhova, V.A.; Chegodaev, Y.S.; Wu, W.; Orekhov, A.N. Oxidative stress and antioxidants in athero-sclerosis development and treatment. Biology 2020, 9, 60. [Google Scholar] [CrossRef] [PubMed]
- Batty, M.; Bennett, M.R.; Yu, E. The role of oxidative stress in atherosclerosis. Cells 2022, 11, 3843. [Google Scholar] [CrossRef]
- Kattoor, A.J.; Pothineni, N.V.K.; Palagiri, D.; Mehta, J.L. Oxidative Stress in Atherosclerosis. Curr. Atheroscler. Rep. 2017, 19, 42. [Google Scholar] [CrossRef]
- Le, N.-A. Lipoprotein-associated oxidative stress: A new twist to the postprandial hypothesis. Int. J. Mol. Sci. 2015, 16, 401–419. [Google Scholar] [CrossRef]
- Ito, F.; Sono, Y.; Ito, T. Measurement and clinical significance of lipid peroxidation as a biomarker of oxidative stress: Oxidative stress in diabetes, atherosclerosis, and chronic inflammation. Antioxidants 2019, 8, 72. [Google Scholar] [CrossRef]
- Ayala, A.; Muñoz, M.F.; Argüelles, S. Lipid peroxidation: Production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid. Med. Cell. Longev. 2014, 2014, 360438. [Google Scholar] [CrossRef] [PubMed]
- Papac-Milicevic, N.; Busch, C.; Binder, C. Malondialdehyde epitopes as targets of immunity and the implications for atherosclerosis. Adv. Immunol. 2016, 131, 1–59. [Google Scholar]
- Bastani, A.; Rajabi, S.; Daliran, A.; Saadat, H.; Karimi-Busheri, F. Oxidant and antioxidant status in coronary artery disease. Biomed. Rep. 2018, 9, 327–332. [Google Scholar] [CrossRef] [PubMed]
- Malekmohammad, K.; Sewell, R.D.E.; Rafieian-Kopaei, M. Antioxidants and atherosclerosis: Mechanistic Aspects. Biomolecules 2019, 9, 301. [Google Scholar] [CrossRef]
- Mazgelytė, E.; Karčiasukaitė, D.; Linkevičiūtė, A.; Mažeikienė, A.; Burokienė, N.; Matuzevičienė, R.; Kučinskienė, Z.A. Association of hair cortisol concentration with prevalence of major cardiovascular risk factors and allostatic load. Med. Sci. Monit. 2019, 25, 3573–3582. [Google Scholar] [CrossRef] [PubMed]
- Mas-Bargues, C.; Escrivá, C.; Dromant, M.; Borrás, C.; Viña, J. Lipid peroxidation as measured by chromatographic determination of malondialdehyde. Human plasma reference values in health and disease. Arch. Biochem. Biophys. 2021, 709, 108941. [Google Scholar] [CrossRef]
- Pinchuk, I.; Weber, D.; Kochlik, B.; Stuetz, W.; Toussaint, O.; Debacq-Chainiaux, F.; Dollé, M.E.; Jansen, E.H.; Gonos, E.S.; Sikora, E.; et al. Gender- and age-dependencies of oxidative stress, as detected based on the steady state concentrations of different biomarkers in the MARK-AGE study. Redox. Biol. 2019, 24, 101204. [Google Scholar] [CrossRef]
- Fasna, K.A.; Geetha, N.; Maliekkal, J. Oxidative stress in ageing. Int. J. Res. Med. Sci. 2017, 5, 4826. [Google Scholar]
- Liguori, I.; Russo, G.; Curcio, F.; Bulli, G.; Aran, L.; Della-Morte, D.; Abete, P. Oxidative stress, aging, and diseases. Clin. Interv. Aging 2018, 13, 757–772. [Google Scholar] [CrossRef]
- Warraich, U.-E.; Hussain, F.; Kayani, H.U.R. Aging-oxidative stress, Antioxidants and computational modeling. Heliyon 2020, 6, e04107. [Google Scholar] [CrossRef]
- Limberaki, E.; Eleftheriou, P.; Vagdatli, E.; Kostoglou, V.; Petrou, C. Serum antioxidant status among young, middle-aged and elderly people before and after antioxidant rich diet. Hippokratia 2012, 16, 118–123. [Google Scholar]
- Ngo, V.; Duennwald, M.L. Nrf2 and oxidative stress: A general overview of mechanisms and implications in human disease. Antioxidants 2022, 11, 2345. [Google Scholar] [CrossRef]
- Gawron-Skarbek, A.; Chrzczanowicz, J.; Kostka, J.; Nowak, D.; Drygas, W.; Jegier, A.; Kostka, T. Cardiovascular risk factors and total serum antioxidant capacity in healthy men and in men with coronary heart disease. BioMed Res. Int. 2014, 2014, 216964. [Google Scholar] [CrossRef] [PubMed]
- Mozaffari, H.; Daneshzad, E.; Larijani, B.; Surkan, P.J.; Azadbakht, L. Association of dietary total antioxidant capacity to anthro-pometry in healthy women: A cross-sectional study. Nutrition 2020, 69, 110577. [Google Scholar] [CrossRef] [PubMed]
- Dzięgielewska-Gęsiak, S.; Płóciniczak, A.; Wilemska-Kucharzewska, K.; Kokot, T.; Muc-Wierzgoń, M.; Wysocka, E. The relationship between plasma lipids, oxidant–antioxidant status, and glycated proteins in individuals at risk for atherosclerosis. Clin. Interv. Aging 2019, 14, 789–796. [Google Scholar] [CrossRef]
- Atamer, A.; Kurdas-Ovunc, A.; Yesil, A.; Atamer, Y. Evaluation of paraoxonase, Malondialdehyde, and lipoprotein levels in patients with asymptomatic cholelithiasis. Saudi J. Gastroenterol. 2014, 20, 66–73. [Google Scholar] [CrossRef]
- Visseren, F.L.J.; Mach, F.; Smulders, Y.M.; Carballo, D.; Koskinas, K.C.; Bäck, M.; Benetos, A.; Biffi, A.; Boavida, J.-M.; Capodanno, D.; et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur. J. Prev. Cardiol. 2022, 29, 5–115. [Google Scholar] [CrossRef] [PubMed]
- Lee, R.; Margaritis, M.; Channon, K.M.; Antoniades, C. Evaluating oxidative stress in human cardiovascular disease: Methodological aspects and considerations. Curr. Med. Chem. 2012, 19, 2504–2520. [Google Scholar] [CrossRef]
- Stephens, J.W.; Khanolkar, M.P.; Bain, S.C. The biological relevance and measurement of plasma markers of oxidative stress in diabetes and cardiovascular disease. Atherosclerosis 2009, 202, 321–329. [Google Scholar] [CrossRef]
- Kander, M.C.; Cui, Y.; Liu, Z. Gender difference in oxidative stress: A new look at the mechanisms for cardiovascular diseases. J. Cell. Mol. Med. 2017, 21, 1024–1032. [Google Scholar] [CrossRef]
- Ko, S.-H.; Kim, H.-S. Menopause-associated lipid metabolic disorders and foods beneficial for postmenopausal women. Nutrients 2020, 12, 202. [Google Scholar] [CrossRef] [PubMed]
Variable (n = 86) | Mean ± SD or Median (IQR) | Range |
---|---|---|
Anthropometric parameters | ||
Age (years) | 55 (7) | 50–64 |
BMI * (kg/m2) | 27.98 ± 5.45 | 17.97–43.44 |
Waist circumference (cm) | 87.86 ± 12.23 | 62.00–127.00 |
Lipid metabolism biomarkers | ||
ApoAI * (g/L) | 1.54 (0.25) | 0.86–2.49 |
ApoB * (g/L) | 0.91 (0.35) | 0.09–1.61 |
Total cholesterol (mmol/L) | 5.80 (1.41) | 4.13–10.69 |
HDL cholesterol * (mmol/L) | 1.59 (0.62) | 0.85–2.90 |
LDL cholesterol * (mmol/L) | 3.47 (1.07) | 1.95–8.88 |
Non-HDL cholesterol * (mmol/L) | 4.01 (1.34) | 2.78–9.47 |
Triacylglycerols (mmol/L) | 1.15 (0.82) | 0.53–3.54 |
Antioxidative system and oxidative stress biomarkers | ||
TAC * (µmol/L) | 394.6 (112.22) | 154.20–1187.50 |
SOD inhibition rate * (%) | 76.08 (8.26) | 53.24–89.22 |
Malondialdehyde (µmol/L) | 1.72 (0.55) | 0.77–3.78 |
Parameter | MDA * < 1.72 (µmol/L) | MDA * ≥ 1.72 (µmol/L) | p-Value |
---|---|---|---|
Age (years) | 54 (6.5) | 56 (7.0) | 0.014 |
BMI * (kg/m2) | 26.70 (7.64) | 27.14 (7.88) | 0.832 |
Waist circumference (cm) | 85 (14.5) | 86 (18.5) | 0.873 |
Parameter | TAC *< 394.6 (µmol/L) | TAC * ≥ 394.6 (µmol/L) | p-Value | SOD Inhibition Rate * < 76.08 (%) | SOD Inhibition Rate * ≥ 76.08 (%) | p-Value |
---|---|---|---|---|---|---|
Age (years) | 54 (6.0) | 56 (7.0) | 0.205 | 54 (7.0) | 55 (7.0) | 0.558 |
BMI * (kg/m2) | 24.34 (4.05) | 29.76 (6.94) | 3.384 × 10−5 | 26.95 (7.80) | 27.14 (8.36) | 0.816 |
Waist circumference (cm) | 80 (10.5) | 93 (14.0) | 3.539 × 10−5 | 89 (16.5) | 85 (15.5) | 0.551 |
Parameter | MDA * (µmol/L) | TAC * (µmol/L) | SOD Inhibition Rate * (%) |
---|---|---|---|
Age (years) | R = 0.28, p = 0.009 | R = 0.22, p = 0.039 | R = 0.03, p = 0.759 |
BMI * (kg/m2) | R = 0.06, p = 0.581 | R = 0.43, p = 3.319 × 10−5 | R = −0.002, p = 0.988 |
Waist circumference (cm) | R = 0.05, p = 0.587 | R = 0.42, p = 6.68 × 10−5 | R = −0.08, p = 0.456 |
Parameter | MDA * < 1.72 (µmol/L) | MDA * ≥ 1.72 (µmol/L) | p-Value |
---|---|---|---|
ApoAI * (g/L) | 1.51 (0.26) | 1.54 (0.33) | 0.138 |
ApoB * (g/L) | 0.87 (0.27) | 0.93 (0.37) | 0.049 |
Total cholesterol (mmol/L) | 5.26 (1.36) | 6.18 (1.14) | 0.007 |
HDL cholesterol * (mmol/L) | 1.53 (0.56) | 1.63 (0.63) | 0.118 |
LDL cholesterol * (mmol/L) | 3.33 (1.25) | 3.56 (0.92) | 0.194 |
Non-HDL cholesterol * (mmol/L) | 3.84 (1.34) | 4.14 (1.53) | 0.077 |
Triacylglycerols (mmol/L) | 1.03 (0.65) | 1.23 (0.81) | 0.136 |
Parameter | TAC * < 394.6 (µmol/L) | TAC * ≥ 394.6 (µmol/L) | p-Value | SOD Inhibition Rate * < 76.08 (%) | SOD Inhibition Rate * ≥ 76.08 (%) | p-Value |
---|---|---|---|---|---|---|
ApoAI * (g/L) | 1.54 (0.33) | 1.50 (0.22) | 0.720 | 1.54 (0.23) | 1.53 (0.34) | 0.666 |
ApoB * (g/L) | 0.85 (0.17) | 0.97 (0.37) | 0.012 | 0.85 (0.32) | 0.95 (0.32) | 0.034 |
Total cholesterol (mmol/L) | 5.62 (1.27) | 6.01 (1.46) | 0.364 | 5.46 (1.30) | 6.01 (1.23) | 0.110 |
HDL cholesterol * (mmol/L) | 1.64 (0.64) | 1.53 (0.54) | 0.245 | 1.56 (0.49) | 1.61 (0.68) | 0.601 |
LDL cholesterol * (mmol/L) | 3.45 (0.87) | 3.56 (1.17) | 0.966 | 3.25 (1.13) | 3.61 (0.92) | 0.203 |
Non-HDL cholesterol * (mmol/L) | 3.98 (0.96) | 4.27 (1.60) | 0.238 | 3.88 (1.42) | 4.27 (1.26) | 0.108 |
Triacylglycerols (mmol/L) | 0.96 (0.45) | 1.58 (0.92) | 1.671 × 10−6 | 1.11 (0.50) | 1.28 (1.06) | 0.146 |
Parameter | MDA * (µmol/L) | TAC * (µmol/L) | SOD Inhibition Rate * (%) |
---|---|---|---|
ApoAI * (g/L) | R = 0.17, p = 0.111 | R = 0.02, p = 0.869 | R = −0.02, p = 0.859 |
ApoB * (g/L) | R = 0.32, p = 0.003 | R = 0.37, p = 5.085 *10−4 | R = 0.22, p = 0.034 |
Total cholesterol (mmol/L) | R = 0.35, p = 0.001 | R = 0.20, p = 0.063 | R = 0.22, p = 0.034 |
HDL cholesterol * (mmol/L) | R = 0.12, p = 0.288 | R = −0.09, p = 0.397 | R = −0.07, p = 0.498 |
LDL cholesterol * (mmol/L) | R = 0.20, p = 0.063 | R = 0.08, p = 0.454 | R = 0.13, p = 0.221 |
Non-HDL cholesterol * (mmol/L) | R = 0.26, p = 0.016 | R = 0.21, p = 0.051 | R = 0.21, p = 0.055 |
Triacylglycerols (mmol/L) | R = 0.24, p = 0.024 | R = 0.54, p = 7.289 *10−8 | R = 0.22, p = 0.034 |
Parameter | BMI * < 25.0 (kg/m2) | BMI * ≥ 25.0 (kg/m2) | p-Value | WC * < 88.0 (cm) | WC * ≥ 88.0 (cm) | p-Value |
---|---|---|---|---|---|---|
N | 32 | 54 | - | 45 | 51 | - |
MDA * (µmol/L) | 1.73 (0.62) | 1.70 (0.51) | 0.968 | 1.71 (0.51) | 1.73 (0.54) | 0.202 |
TAC * (µmol/L) | 337.84 (87.19) | 421.92 (92.77) | 4.038 × 10−5 | 349.65 (98.93) | 422.15 (108.75) | 1.313 × 10−4 |
SOD inhibition rate * (%) | 76.33 (0.87) | 76.08 (8.28) | 1.000 | 76.87 (8.21) | 75.08 (9.62) | 0.492 |
Parameter | Normolipidemic Group | Dyslipidemia Group | p-Value |
---|---|---|---|
N | 32 | 54 | - |
MDA * (µmol/L) | 1.58 (0.41) | 1.79 (0.60) | 3.946 × 10−2 |
TAC * (µmol/L) | 386.97 (107.08) | 402.14 (116.38) | 0.911 |
SOD inhibition rate * (%) | 75.85 (5.60) | 76.84 (9.23) | 0.514 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Černiauskas, L.; Mažeikienė, A.; Mazgelytė, E.; Petrylaitė, E.; Linkevičiūtė-Dumčė, A.; Burokienė, N.; Karčiauskaitė, D. Malondialdehyde, Antioxidant Defense System Components and Their Relationship with Anthropometric Measures and Lipid Metabolism Biomarkers in Apparently Healthy Women. Biomedicines 2023, 11, 2450. https://doi.org/10.3390/biomedicines11092450
Černiauskas L, Mažeikienė A, Mazgelytė E, Petrylaitė E, Linkevičiūtė-Dumčė A, Burokienė N, Karčiauskaitė D. Malondialdehyde, Antioxidant Defense System Components and Their Relationship with Anthropometric Measures and Lipid Metabolism Biomarkers in Apparently Healthy Women. Biomedicines. 2023; 11(9):2450. https://doi.org/10.3390/biomedicines11092450
Chicago/Turabian StyleČerniauskas, Linas, Asta Mažeikienė, Eglė Mazgelytė, Eglė Petrylaitė, Aušra Linkevičiūtė-Dumčė, Neringa Burokienė, and Dovilė Karčiauskaitė. 2023. "Malondialdehyde, Antioxidant Defense System Components and Their Relationship with Anthropometric Measures and Lipid Metabolism Biomarkers in Apparently Healthy Women" Biomedicines 11, no. 9: 2450. https://doi.org/10.3390/biomedicines11092450